Elly Gerald Stoica

Array ( [id] => 18603420 [patent_doc_number] => 11744860 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-05 [patent_title] => Technology for efficient activation of NKT cells [patent_app_type] => utility [patent_app_number] => 16/096561 [patent_app_country] => US [patent_app_date] => 2017-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 26 [patent_no_of_words] => 16168 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16096561 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12205862 [patent_doc_number] => 20180051088 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-22 [patent_title] => 'ACTRIIB BINDING AGENTS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/477204 [patent_app_country] => US [patent_app_date] => 2017-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 23138 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15477204 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14485141 [patent_doc_number] => 10329337 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-06-25 [patent_title] => Method to increase the number of circulating platelets by administering PEGylated cysteine variants of IL-11 [patent_app_type] => utility [patent_app_number] => 15/470041 [patent_app_country] => US [patent_app_date] => 2017-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25937 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 309 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15470041 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13690189 [patent_doc_number] => 20170356049 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-14 [patent_title] => MONOCLONAL AND OLIGOCLONAL ANTI-EGFR ANTIBODIES FOR USE IN THE TREATMENT OF TUMORS EXPRESSING PREDOMINANTLY HIGH AFFINITY EGFR LIGANDS OR TUMORS EXPRESSING PREDOMINANTLY LOW AFFINITY EGFR LIGANDS [patent_app_type] => utility [patent_app_number] => 15/462738 [patent_app_country] => US [patent_app_date] => 2017-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7350 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 131 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15462738 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14132425 [patent_doc_number] => 20190100602 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-04 [patent_title] => ANTI-ANTITHROMBIN SINGLE-DOMAIN ANTIBODIES AND POLYPEPTIDES COMPRISING THEREOF [patent_app_type] => utility [patent_app_number] => 16/086146 [patent_app_country] => US [patent_app_date] => 2017-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17922 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16086146 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14075035 [patent_doc_number] => 20190086405 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-21 [patent_title] => METHODS OF DIAGNOSING AND TREATING LUPUS [patent_app_type] => utility [patent_app_number] => 16/085007 [patent_app_country] => US [patent_app_date] => 2017-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14517 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16085007 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14388395 [patent_doc_number] => 10307455 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-06-04 [patent_title] => Activin type 2 receptor antibodies [patent_app_type] => utility [patent_app_number] => 15/456392 [patent_app_country] => US [patent_app_date] => 2017-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 55 [patent_no_of_words] => 69260 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 2723 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15456392 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14978297 [patent_doc_number] => 10443054 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-15 [patent_title] => Methods for identifying and treating invasive/metastatic breast cancers [patent_app_type] => utility [patent_app_number] => 15/451374 [patent_app_country] => US [patent_app_date] => 2017-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 96 [patent_no_of_words] => 28779 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15451374 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13265715 [patent_doc_number] => 10144934 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-12-04 [patent_title] => Targeted/TGF-ssRII fusion proteins and methods for making same [patent_app_type] => utility [patent_app_number] => 15/444527 [patent_app_country] => US [patent_app_date] => 2017-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 65 [patent_figures_cnt] => 65 [patent_no_of_words] => 13095 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 293 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15444527 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11964937 [patent_doc_number] => 20170269091 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-21 [patent_title] => 'USP14 AS A BIOMARKER FOR PREDICTING RECURRENCE IN ENDOMETRIAL AND OVARIAN CANCER' [patent_app_type] => utility [patent_app_number] => 15/443417 [patent_app_country] => US [patent_app_date] => 2017-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 22846 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15443417 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11944457 [patent_doc_number] => 20170248608 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-31 [patent_title] => 'Epidermal Growth Factor Receptor (EGFR) Protein SRM Assay' [patent_app_type] => utility [patent_app_number] => 15/444310 [patent_app_country] => US [patent_app_date] => 2017-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 6505 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15444310 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13179637 [patent_doc_number] => 10105306 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-23 [patent_title] => Method of preparing a growth factor concentrate [patent_app_type] => utility [patent_app_number] => 15/436890 [patent_app_country] => US [patent_app_date] => 2017-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 5431 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 226 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15436890 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13902383 [patent_doc_number] => 20190040396 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-07 [patent_title] => Combination Therapy [patent_app_type] => utility [patent_app_number] => 16/076981 [patent_app_country] => US [patent_app_date] => 2017-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14893 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16076981 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18043692 [patent_doc_number] => 11517626 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-06 [patent_title] => Pyrrolobenzodiazepine antibody conjugates [patent_app_type] => utility [patent_app_number] => 16/076595 [patent_app_country] => US [patent_app_date] => 2017-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 32309 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16076595 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13955603 [patent_doc_number] => 20190054145 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-21 [patent_title] => SYNERGISTIC TUMOR TREATMENT WITH IL-2, AN INTEGRIN-BINDING-FC FUSION PROTEIN, AND A CANCER VACCINE [patent_app_type] => utility [patent_app_number] => 16/076597 [patent_app_country] => US [patent_app_date] => 2017-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40378 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -60 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16076597 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11662639 [patent_doc_number] => 20170151345 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-01 [patent_title] => 'COMPOSITIONS AND METHODS FOR TREATING CANCER' [patent_app_type] => utility [patent_app_number] => 15/426079 [patent_app_country] => US [patent_app_date] => 2017-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 41366 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15426079 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17292249 [patent_doc_number] => 20210388088 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => TARGETED THERAPEUTIC AGENTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/075323 [patent_app_country] => US [patent_app_date] => 2017-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26504 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16075323 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11850289 [patent_doc_number] => 20170224781 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-10 [patent_title] => 'Y1 receptor activator for treating an anticancer agent-induced nephrotoxic injury' [patent_app_type] => utility [patent_app_number] => 15/424185 [patent_app_country] => US [patent_app_date] => 2017-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 6514 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15424185 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13899115 [patent_doc_number] => 20190038762 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-07 [patent_title] => GCC-TARGETED ANTIBODY-DRUG CONJUGATES [patent_app_type] => utility [patent_app_number] => 16/075023 [patent_app_country] => US [patent_app_date] => 2017-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20189 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16075023 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11995443 [patent_doc_number] => 20170299598 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-19 [patent_title] => 'Methods and Monitoring of Treatment With A DLL4 Antagonist' [patent_app_type] => utility [patent_app_number] => 15/421635 [patent_app_country] => US [patent_app_date] => 2017-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 28922 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15421635 [rel_patent_id] =>[rel_patent_doc_number] =>)